Greg Crimmins, PhD is the Founder and CEO of Remedy Plan Therapeutics. Greg began his scientific training in developmental biology as an undergrad at the University of Illinois Urbana-Champaign. He completed his PhD at UC Berkeley and a postdoc at Tufts University, where he focused on solving complex biological questions using genetics and high-throughput phenotypic screening to discover new aspects of both bacteria and the human immune system. This foundation led him to start Remedy Plan Therapeutics in 2016, founded on the conviction that a high-throughput phenotypic screening platform could be used to discover brand new cancer therapeutics would make a lasting impact in the lives of many.